Fundacao Antonio Prudente, AC Camargo Cancer Center

São Paulo, São Paulo 01509-900

1 studies enrolling now · 5 studies all time

What they study most

Advanced Cholangiocarcinoma, Endometrial Cancer Stage I, Extensive-Stage Small-Cell Lung Cancer, FGFR2 Gene Rearrangements, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma, Metastatic Colorectal Cancer, Sentinel Lymph Node, Small-Cell Lung Cancer, Surgery

Studies at this site

• Study of Sotorasib, Panitumumab and FOLFIRI Versus FOLFIRI With or Without Bevacizumab-awwb in Treatment-naïve Participants With Metastatic Colorectal Cancer With KRAS p.G12C Mutation — Recruiting now
• Sentinel Node Biopsy in Endometrial Cancer — Recruiting now
• Bemarituzumab Plus Chemotherapy and Nivolumab Versus Chemotherapy and Nivolumab for FGFR2b Overexpressed Untreated Advanced Gastric and Gastroesophageal Junction Cancer. — Stopped early
• Study Comparing Tarlatamab and Durvalumab Versus Durvalumab Alone in First-Line Extensive-Stage Small-Cell Lung Cancer (ES-SCLC) Following Platinum, Etoposide and Durvalumab — Running, not enrolling
• Futibatinib Versus Gemcitabine-Cisplatin Chemotherapy as First-Line Treatment of Patients With Advanced Cholangiocarcinoma Harboring FGFR2 Gene Rearrangements — Stopped early